UPCOMING EVENTS
NEWS
ErythroMer Featured in Drug Discovery News – December 2022/January 2023 Issue
Facing donor shortages and storage limitations, researchers are developing synthetic red blood cells, platelets, and plasma and combining them into artificial blood.
DARPA Team Begins Work on Field Deployable Whole Blood Equivalent
KaloCyte to participate in DARPA’s Fieldable Solutions for Hemorrhage with bio-
Artificial Resuscitation Products (FSHARP) program, to develop a field-deployable, shelf-stable
whole blood equivalent that can be used to resuscitate trauma patients when donated blood
products are not available.
David J. Ramsay Entrepreneur of the Year Video Presentation
The University of Maryland, Baltimore (UMB) produced this video showcasing the work of KaloCyte Co-Founder and Chief Scientific Officer, Allan Doctor MD; recipient of the 2022
2022 UMB Entrepreneur of the Year Awards Presentation
On October 24, 2022 this year’s David J. Ramsay Entrepreneur of the Year Awards winner Allan Doctor, MD, gave a lecture demonstrating the impact his entrepreneurship and research have had on the community and UMB.
UMB Honors KaloCyte Co-Founder Allan Doctor, MD as David J. Ramsay Entrepreneur of the Year
The University of Maryland, Baltimore (UMB) has announced the recipients of their 2022 Founders Week awards in recognition of the extraordinary work of the UMB community, including KaloCyte Co-Founder and Chief Scientific Officer, Allan Doctor, MD
New Book Released: “Blood Substitutes and Oxygen Biotherapeutics”; Henry Liu, Alan D. Kaye, and Jonathan S. Jahr; Editors
This new book features a full chapter co-authored by KaloCyte’s Research and Development team and serves as a comprehensive and authoritative reference book in blood transfusion and blood substitutes. It is a collection of the latest developments and the newest investigations, and individual chapters are written by world experts in the arena.
State of the Art Report: Nanotechnology Applications for Combat Casualty Care – HDIAC
ErythroMer™ featured in the August 2022 State of the Art report issued by the Homeland Defense & Security Information Analysis Center (HDIAC)
KaloCyte Closes Investment from New York Blood Center
KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMer™, announced it has closed an investment from New York Blood Center, Inc. (NYBC).
KaloCyte with the Angel Capital Association – Innovation Showcase Winners
Mark it on your calendar! On June 9, at 4:00 PM EST, our KaloCyte will join other Innovation Showcase winners pitching again in an exclusive online event in which each winner, chosen by ACA Summit attendees, will have 10 minutes to pitch.
A Strategic Relocation to Baltimore Supports one Biomedical Company’s Growth
KaloCyte’s Co-founders made the best of both worlds right in the heart of Baltimore: The St. Louis-founded startup moved into CBOTH as a University of Maryland BioPark affiliate in July 2019.
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by nearly $20M in federal grants and investor funding.